AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg
Source: SeekingAlpha
2026-03-07 13:16:21 ET
More on AtaiBeckley
- AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript
- AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder - Slideshow
- AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
- Psychedelics stocks could benefit from marijuana rescheduling: Jefferies
- Seeking Alpha’s Quant Rating on AtaiBeckley
Read the full article on Seeking Alpha
For further details see:
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg
ATAI Life Sciences N.V.
NASDAQ: ATAI
ATAI Trading
5.79% G/L:
$3.745 Last:
5,347,264 Volume:
$3.40 Open:
ATAI Latest News
March 09, 2026 10:50:00 am
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
March 06, 2026 07:00:00 am
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
March 03, 2026 07:00:00 am
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
ATAI Stock Data
$1,443,705,400
301,295,593
0.1%
45
N/A
Biotechnology & Life Sciences
Healthcare
DE
Amstelveen
